Neumora Therapeutics, Inc. (NMRA) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $182.53M | +28.4% |
| 2024 | $142.15M | -62.0% |
| 2023 | $374.04M | +55.2% |
| 2022 | $240.94M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $182.53M | +28.4% |
| 2024 | $142.15M | -62.0% |
| 2023 | $374.04M | +55.2% |
| 2022 | $240.94M | — |